MyChem

MyChem is a specialized manufacturer of ultra-pure synthetic nucleotides, serving the life sciences research and diagnostic markets, particularly next-generation sequencing. Founded in 2007 and based in San Diego, it has been acquired by TriLink Biotechnologies, integrating it into a larger supply chain for nucleic acid-based technologies. The company's value proposition centers on high-purity, scalable production of modified nucleotides free from enzymatic contaminants. Its business model is service and product-based, providing essential raw materials to the genomics and biotechnology industries.

Synthetic chemistry platform for scalable production of ultra-pure natural and modified nucleotides (triphosphates, phosphoramidites, nucleosides), emphasizing absence of cross-base contamination and enzymatic activities.

MyChem competes in the niche market for high-purity synthetic nucleotides against specialized firms like Jena Bioscience and J&K Scientific, as well as large, diversified life science tools companies such as Thermo Fisher Scientific and Merck MilliporeSigma. Its differentiation lies in its specific focus on ultra-purity for NGS and its scale-up capabilities, now amplified by the commercial and manufacturing infrastructure of TriLink and Maravai.